Atherosclerotic Plaque Regression & Vascular Remodeling: Nanomedicine & siRNA Therapeutics

Pathophysiology of Atheroma Formation: Subendothelial Retention & Necrotic Cores

Atherogenesis begins with the subendothelial retention of apolipoprotein B-100 (ApoB)-containing lipoproteins within the tunica intima of susceptible arterial branches and bifurcations. Under conditions of endothelial shear stress, low-density lipoproteins (LDL) and triglyceride-rich remnants cross the vascular endothelium via transcytosis and bind electrostatically to negatively charged extracellular matrix proteoglycans—principally biglycan and versican.

Once trapped within the intima, sequestered lipoproteins undergo extensive oxidative modification, enzymatic cleavage by secretory phospholipases, and non-enzymatic glycation, generating oxidized low-density lipoprotein (oxLDL). Oxidized phospholipids stimulate overlying endothelial cells to upregulate adhesion molecules (vascular cell adhesion molecule-1 [VCAM-1], intercellular adhesion molecule-1 [ICAM-1]) and discharge monocyte chemoattractant protein-1 (MCP-1/CCL2), recruiting circulating monocytes into the subendothelial space.

Within the intima, monocytes differentiate into tissue macrophages expressing scavenger receptors (SR-A1, CD36) that internalize oxLDL through unregulated endocytosis. Because scavenger receptor transcription is not subject to negative feedback inhibition by intracellular cholesterol accumulation, macrophages engulf excessive quantities of esterified cholesterol, becoming lipid-laden foam cells. Over time, persistent lipid loading induces endoplasmic reticulum stress, triggering macrophage apoptosis.

In early physiological conditions, dying macrophages are swiftly engulfed and cleared by neighboring viable phagocytes in a process known as efferocytosis. However, in advancing atherosclerotic lesions, chronic inflammation downregulates the efferocytic receptor MerTK and cleaves the bridging molecule Gas6. Defective efferocytosis leads to secondary necrosis of apoptotic foam cells, cellular lysis, and the release of unesterified free cholesterol, inflammatory microparticles, and matrix metalloproteinases into the intercellular space, forming the lipid-rich necrotic core characteristic of vulnerable thin-cap fibroatheromas (TCFA).

Targeted Nanomedicine & Macrophage Reprogramming

Halting and reversing plaque progression requires not only aggressive systemic lipid lowering, but the active therapeutic resolution of chronic intraplaque inflammation. Targeted nanomedicine offers unprecedented bioengineering strategies to deliver immunomodulatory and pro-resolving agents directly to inflamed arterial lesions while minimizing systemic toxicities:

• Synthetic HDL-Mimetic Nanoparticles: Reconstituted high-density lipoprotein (rHDL) nanoparticles engineered with human apolipoprotein A-I (ApoA-I) and synthetic phospholipids mimic endogenous nascent disc-like HDL. When injected intravenously, these nanocarriers traverse dysfunctional endothelial fenestrations, penetrate deep into the necrotic core, and interact with ATP-binding cassette transporters ABCA1 and ABCG1 on foam cells, stimulating rapid efflux of unesterified cholesterol into reverse cholesterol transport pathways.
• Receptor-Targeted Polymeric Nanocarriers: Biocompatible nanoparticles constructed from poly(lactic-co-glycolic acid) (PLGA) are surface-functionalized with peptide ligands targeting VCAM-1 or the scavenger receptor CD36. These nanocarriers selectively endocytose into plaque macrophages, delivering therapeutic payloads such as synthetic Liver X Receptor (LXR) agonists. By selectively activating LXR in vascular macrophages without inducing hepatic lipogenesis, these nanocarriers upregulate cholesterol export pumps and suppress NF-kappaB transcription.
• Pro-Resolving Nanotherapeutics: Plaque instability is exacerbated by an imbalance between pro-inflammatory leukotrienes and specialized pro-resolving lipid mediators (SPMs, including resolvins and protectins). Nanoparticles encapsulating resolvin D1 (RvD1) or annexin A1-derived peptides restore macrophage efferocytosis, suppress matrix metalloproteinase-9 (MMP-9) synthesis, and promote collagen synthesis by vascular smooth muscle cells, structurally stabilizing the fibrous cap.

Small Interfering RNA (siRNA) Gene Silencing: The Inclisiran Architecture

The most significant pharmacological breakthrough in lipidology over the past decade is the clinical development of small interfering RNA (siRNA) therapeutics that silence specific hepatic mRNA transcripts via endogenous RNA interference (RNAi).

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a circulating serine protease synthesized primarily by hepatocytes that binds to extracellular LDL receptors (LDLR) on the hepatocyte surface. Upon endocytosis of the LDLR-LDL complex, PCSK9 prevents the conformational change required for receptor recycling, shunting the LDL receptor to the lysosome for destruction. By accelerating LDLR degradation, circulating PCSK9 limits hepatic clearance of LDL-C from the bloodstream.

Inclisiran is a synthetic double-stranded siRNA duplex that specifically silences hepatic PCSK9 expression. Its molecular architecture exhibits two critical bioengineering enhancements:

1. Chemical Ribose Backbone Modifications: Multiple 2'-O-methyl and 2'-fluoro ribonucleotide substitutions and phosphorothioate linkages render the siRNA duplex resistant to circulating endonucleases, preventing in vivo degradation.
2. Triantennary GalNAc Conjugation: The sense strand of inclisiran is covalently coupled to a triantennary N-acetylgalactosamine (GalNAc) ligand. GalNAc binds with nanomolar affinity to the asialoglycoprotein receptor (ASGPR)—a high-capacity, hepatocyte-specific endocytic receptor. This ensures virtually 100% hepatic uptake while sparing renal and cardiac tissues.

Upon clathrin-mediated endocytosis into hepatocytes, the antisense strand of inclisiran incorporates into the cytosolic RNA-Induced Silencing Complex (RISC) and activates the catalytic endonuclease Argonaute-2 (AGO2). AGO2 cleaves hepatic PCSK9 mRNA at a single sequence-specific phosphodiester bond, preventing protein translation. Because the active RISC complex remains stable in the cytoplasm for months, twice-yearly subcutaneous administration of inclisiran achieves sustained, durable 50% to 55% reductions in circulating LDL-C and ApoB, eliminating the compliance hurdles of daily oral statins or bi-weekly monoclonal antibodies.

Intravascular Imaging & Clinical Protocols for Plaque Stabilization

Modern clinical trials have transitioned from relying solely on surrogate serum lipid panels to directly visualizing arterial architecture using multi-modality intracoronary imaging:

Optical Coherence Tomography (OCT): Utilizing near-infrared light with a wavelength of approximately 1,300 nanometers, OCT achieves an axial resolution of 10 to 15 micrometers—ten times finer than intravascular ultrasound. OCT provides precise measurement of the fibrous cap thickness (FCT). In unstable thin-cap fibroatheromas, the fibrous cap measures less than 65 micrometers, putting the patient at immediate risk of plaque rupture. In serial OCT trials (such as HUYGENS), driving LDL-C below 40 mg/dL with PCSK9 inhibitors increased fibrous cap thickness by an average of 42 micrometers while significantly shrinking the circumferential lipid arc.

Near-Infrared Spectroscopy (NIRS): Integrated NIRS-IVUS catheters illuminate the coronary vessel wall and analyze diffuse reflectance spectra to generate a chemogram that quantifies the lipid core burden index (LCBI). Serial regression trials demonstrate that intensive lipid lowering coupled with vascular anti-inflammatory therapy drives significant reductions in maxLCBI4mm (the maximum lipid burden in any 4-millimeter segment), converting high-risk unstable soft plaques into quiescent, calcified, structurally stable scars.

For clinical primary care and cardiology practitioners, achieving plaque regression requires setting aggressive, personalized lipid targets: lowering ApoB < 50 mg/dL (or < 40 mg/dL in recurrent ASCVD), reducing LDL-C < 55 mg/dL, screening Lipoprotein(a) at least once in a lifetime, and maintaining systemic hs-CRP < 1.0 mg/L.